Paul A. Mahon Sells 11,000 Shares of United Therapeutics Corporation (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction dated Thursday, June 26th. The stock was sold at an average price of $285.70, for a total value of $3,142,700.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares in the company, valued at approximately $10,508,331.70. This trade represents a 23.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

United Therapeutics Trading Up 0.1%

NASDAQ:UTHR opened at $284.27 on Friday. The firm has a market capitalization of $12.82 billion, a PE ratio of 11.34, a price-to-earnings-growth ratio of 6.22 and a beta of 0.57. The stock has a 50 day moving average of $301.12 and a 200-day moving average of $324.86. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating the consensus estimate of $6.29 by $0.34. The company had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business’s revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the company earned $6.17 earnings per share. As a group, analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on UTHR. Wells Fargo & Company reiterated an “equal weight” rating and issued a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. JPMorgan Chase & Co. cut their price objective on United Therapeutics from $355.00 to $350.00 and set an “overweight” rating on the stock in a research note on Thursday, May 1st. HC Wainwright restated a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Monday, May 5th. Wall Street Zen cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 2nd. Finally, Morgan Stanley upped their price objective on United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a research note on Thursday, May 1st. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $393.08.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors have recently made changes to their positions in UTHR. SVB Wealth LLC bought a new position in shares of United Therapeutics during the first quarter valued at approximately $32,000. Dunhill Financial LLC grew its holdings in shares of United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 50 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Sound Income Strategies LLC bought a new position in shares of United Therapeutics during the first quarter valued at approximately $49,000. Finally, Brooklyn Investment Group grew its holdings in shares of United Therapeutics by 103.2% during the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 98 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.